Prediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer risk.
Prediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer risk.
复制标题
诊断性循环抗肿瘤激素浓度与前列腺癌风险无关。
DOI：
10.1158/1055-9965.epi-14-0803
复制
发表时间：
2014-11
期刊：
影响因子：
--
通讯作者：
Cook MB
中科院分区：
文献类型：
--
作者：
Sklavos MM;Zhou CK;Pinto LA;Cook MB
尽管有大量的研究，前列腺癌的发病机制仍然知之甚少。与此同时，前列腺特异性抗原（PSA）检测已经改变了前列腺癌病例人群的研究，包括更大比例的无症状和惰性疾病。因此，需要努力鉴定前列腺癌生物标志物，特别是侵袭性疾病的生物标志物，以阐明发病机制并帮助筛选疗效。目前的证据表明，睾丸来源的TGF-β家族肽类-抗苗勒管激素（AMH）的循环浓度降低可能与前列腺癌的发病机制有关。为了验证这一假设，我们使用Beckman Coulter AMH Gen II ELISA在前列腺、肺、结直肠和卵巢（PLCO）癌症筛查试验中嵌套的1，000例病例和1，000例对照中测量了诊断前（队列基线）血清中的AMH浓度。对照组与病例在入组时的年龄、入组年份和随访年份的频率相匹配。采用非条件logistic回归模型，根据随机分组时的年龄进行调整，以估计比值比（OR）和95%置信区间（95%CI）。我们发现，诊断前血清AMH浓度与总前列腺癌风险（ORQ 4 vs. Q1=1.15，95% CI：0.89，1.48; P趋势=0.13）、侵袭性前列腺癌风险（ORQ 4 vs. Q1=1.14，95% CI：0.80，1.63; P趋势=0.51）或非侵袭性前列腺癌风险（ORQ 4 vs. Q1=1.22，95% CI：0.91，1.63; P趋势=0.07）无显著相关性。侵袭性疾病的不同定义并没有有意义地改变这些结果。尽管体外研究将AMH与前列腺癌联系起来，但对男性诊断前循环AMH浓度的首次分析并未提供与前列腺癌风险相关的证据。
Despite considerable research, the pathogenesis of prostate cancer remains poorly understood. Meanwhile, prostate-specific antigen (PSA) testing has shifted prostate cancer case populations for study to include a greater proportion of asymptomatic and indolent disease. Thus, efforts to identify prostate cancer biomarkers—particularly for aggressive disease—are required to elucidate pathogenesis and aid screening efficacy. Current evidence suggests that decreased circulating concentrations of the testis-derived, TGF-β family peptide hormone—anti-Müllerian hormone (AMH)—may be associated with prostate cancer pathogenesis. To test this hypothesis, we measured AMH concentrations in pre-diagnostic (cohort baseline) sera using the Beckman Coulter AMH Gen II ELISA in 1,000 cases and 1,000 controls nested within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Controls were frequency-matched to cases on age at entry, enrollment year, and years of follow-up. Unconditional logistic regression models, adjusted for age at randomization, were used to estimate odds ratios (OR) and 95% confidence intervals (95%CIs). We found that pre-diagnostic serologic AMH concentrations were not significantly associated with total (ORQ4 vs. Q1=1.15, 95% CI:0.89, 1.48; P-trend=0.13), aggressive (ORQ4 vs. Q1=1.14, 95% CI:0.80, 1.63; P-trend=0.51), or non-aggressive (ORQ4 vs. Q1=1.22, 95% CI:0.91, 1.63; P-trend=0.07) prostate cancer risks. Different definitions of aggressive disease did not meaningfully alter these results. Despite in vitro studies linking AMH to prostate cancer, this first analysis of pre-diagnostic, circulating AMH concentrations in men provides no evidence for an association with prostate cancer risk.